Summit Therapeutics Inc. Investing Cash Flow
Summit Therapeutics Inc. (SMMT) reported Investing Cash Flow of $222.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-23
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $222.90M, a 47.80% increase year-over-year.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$238.00K, a 100.15% decline year-over-year.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$485.16M, a 681.15% decline year-over-year.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$71.00K.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$174.31M.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$205.34M.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$587.77M.
- Summit Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$624.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 11 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $222.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $222.66M 10-Q · filed 2026-07-23 | -$262.50M derived: sum of 3 quarters · filed 2026-07-23 | -$262.57M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2026-03-31 | -$238.00K 10-Q · filed 2026-04-30 | -$485.39M derived: sum of 2 quarters · filed 2026-04-30 | -$485.47M derived: sum of 3 quarters · filed 2026-04-30 | -$334.66M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-12-31 | -$485.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$485.23M derived: sum of 2 quarters · filed 2026-02-23 | -$334.42M derived: sum of 3 quarters · filed 2026-07-23 | -$174.31M 10-K · filed 2026-02-23 | |
| 2025-09-30 | -$71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $150.74M derived: sum of 2 quarters · filed 2026-07-23 | $310.85M 10-Q · filed 2025-10-20 | $394.33M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-06-30 | $150.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $310.92M 10-Q · filed 2026-07-23 | $394.40M derived: sum of 3 quarters · filed 2026-07-23 | $285.79M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-03-31 | $160.11M 10-Q · filed 2026-04-30 | $243.59M derived: sum of 2 quarters · filed 2026-04-30 | $134.98M derived: sum of 3 quarters · filed 2026-04-30 | -$65.10M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $83.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$25.13M derived: sum of 2 quarters · filed 2026-02-23 | -$225.21M derived: sum of 3 quarters · filed 2026-02-23 | -$205.34M 10-K · filed 2026-02-23 | |
| 2024-09-30 | -$108.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | -$308.69M derived: sum of 2 quarters · filed 2025-10-20 | -$288.82M 10-Q · filed 2025-10-20 | -$228.25M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | -$200.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$180.21M 10-Q · filed 2025-08-11 | -$119.64M derived: sum of 3 quarters · filed 2026-02-23 | -$123.13M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $19.87M 10-Q · filed 2025-05-01 | $80.44M derived: sum of 2 quarters · filed 2026-02-23 | $76.95M derived: sum of 3 quarters · filed 2026-02-23 | $77.16M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $60.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $57.08M derived: sum of 2 quarters · filed 2026-02-23 | $57.29M derived: sum of 3 quarters · filed 2026-02-23 | -$587.77M 10-K · filed 2026-02-23 | |
| 2023-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$3.28M derived: sum of 2 quarters · filed 2024-10-30 | -$648.34M 10-Q · filed 2024-10-30 | -$648.33M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $207.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$644.86M 10-Q · filed 2024-08-06 | -$644.85M derived: sum of 3 quarters · filed 2025-02-24 | -$644.83M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | -$645.06M 10-Q · filed 2024-05-01 | -$645.05M derived: sum of 2 quarters · filed 2025-02-24 | -$645.03M derived: sum of 3 quarters · filed 2025-02-24 | -$645.33M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $30.00K derived: sum of 2 quarters · filed 2025-02-24 | -$263.00K derived: sum of 3 quarters · filed 2025-02-24 | -$624.00K 10-K · filed 2025-02-24 | |
| 2022-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$273.00K derived: sum of 2 quarters · filed 2023-11-07 | -$634.00K 10-Q · filed 2023-11-07 | -$754.00K derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$293.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$654.00K 10-Q · filed 2023-08-09 | -$774.00K derived: sum of 3 quarters · filed 2023-08-09 | -$770.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$361.00K 10-Q · filed 2023-05-11 | -$481.00K derived: sum of 2 quarters · filed 2023-05-11 | -$477.00K derived: sum of 3 quarters · filed 2023-05-11 | -$628.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$116.00K derived: sum of 2 quarters · filed 2023-03-09 | -$267.00K derived: sum of 3 quarters · filed 2023-03-09 | -$306.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$147.00K derived: sum of 2 quarters · filed 2022-11-09 | -$186.00K 10-Q · filed 2022-11-09 | -$236.00K derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$190.00K 10-Q · filed 2022-08-11 | -$240.00K derived: sum of 3 quarters · filed 2022-12-21 | -$284.00K derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-03-31 | -$39.00K 10-Q · filed 2022-05-11 | -$89.00K derived: sum of 2 quarters · filed 2022-12-21 | -$133.00K derived: sum of 3 quarters · filed 2022-12-21 | -$266.00K derived: sum of 4 quarters · filed 2022-12-21 | |
| 2020-12-31 | -$50.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | -$94.00K derived: sum of 2 quarters · filed 2022-12-21 | -$227.00K derived: sum of 3 quarters · filed 2022-12-21 | -$421.00K 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | -$44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$177.00K derived: sum of 2 quarters · filed 2021-11-15 | -$371.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$327.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$194.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | -$341.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | -$133.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$358.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$225.00K 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | -$331.00K 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | -$7.04M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |